Phase 2
Completed N=163
CAP-Ketamine for Antidepressant Resistant PTSD
Source: ClinicalTrials.gov NCT02655692 ↗Enrolled (actual)
163
Serious AEs
0.0%
Results posted
Jun 2022
Primary outcomePrimary: PTSD Checklist (PCL) — 48.56; 46.62; 47.88 units on a scale
Summary
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PTSD Checklist (PCL) |
48.56; 46.62; 47.88 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| PRIMARY The PTSD Checklist (PCL) |
31.90; 24.32; 31.23 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
| SECONDARY Montgomery-Asberg Depression Rating Scale (MADRS) |
19.45; 15.44; 19.58 | — |
Eligibility Criteria
Inclusion Criteria
- male or female Veterans or active duty military personnel between the ages of 18 and 70 years
- diagnosis of PTSD
- history of trialing one or more antidepressant medications with little to no PTSD symptom improvement
- ability to provide written informed consent
Exclusion Criteria
- females who are currently pregnant or breastfeeding
- current high risk for suicide
- history of severe head injury
Data sourced from ClinicalTrials.gov (NCT02655692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.